Search
Ligand Pharmaceuticals Inc
LGNDAdd to Watchlist
322.750USD
+5.420+1.71%
Close 10-30 16:00（ET）
6.44BMarket Cap
42.04P/E TTM
Ligand Pharmaceuticals Inc (LGND) Stock Price Target & Forecast
Analyst Rating
Based on 11 analysts giving stock ratings to Ligand Pharmaceuticals Inc in the past month.
Buy
5 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
345.750USD+8.46%
LGND Analyst Recommendation Trends
In the current month, LGND has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LGND average Analyst price target in the last month is 345.750.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
5
4
3
3
3
4
6
6
5
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
11
10
9
8
8
8
9
LGND Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
10
17
10
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
5
18
9
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
15
9
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, LGND EPS is projected to reach 2.960 in FY2026Q4, following reported EPS of -1.427 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
1.82
1.82
2.38
2.96
2.30
Actual
-0.67
2.42
-1.43
--
--
Surprise
-136.97%
+32.50%
-159.92%
--
--
FAQs
What is Ligand Pharmaceuticals Inc's expected revenue for the next quarter?
Ligand Pharmaceuticals Inc's expected revenue is 96.60M.
What is Ligand Pharmaceuticals Inc's price target?
Analysts forecast that Ligand Pharmaceuticals Inc's price target is USD 345.75, with the highest forecast at USD 406.00 and the lowest forecast at USD 247.00.
How have Ligand Pharmaceuticals IncLGND's recent earnings per share performed?
The market expectation was USD -1.43, while Ligand Pharmaceuticals IncLGND's earnings per share (EPS) for the previous quarter was USD 2.42. EPS for the next quarter is expected at USD 2.96.
What is the analyst rating for Ligand Pharmaceuticals Inc?
Based on the ratings of Ligand Pharmaceuticals Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.